Interferon and Copolymer I Treatment in Multiple Sclerosis: Clinical and Pathobiological Implications
Multiple sclerosis (MS), although well-described clinically and pathologically for over 120 years, is only now poised for a new era of improved therapy brought about primarily by findings obtained from clinical research. Over the past 12 years, various investigations of new treatments have not only identified effective agents but have provided unexpected new insights into the basic mechanisms of disease activity in MS. The combination of carefully designed and conducted clinical trials, coupled with serial MRI studies of the brain, has allowed us to determine the therapeutic benefit of one and perhaps two treatments with low risk and toxicity which are likely to be available to the general MS community within 6 to 24 months.
KeywordsMultiple Sclerosis Myelin Basic Protein Experimental Allergic Encephalomyelitis Beta Interferon Tamic Acid
Unable to display preview. Download preview PDF.
- 2.The IFN-Multiple Sclerosis Study Group, Interferon-beta 1 B is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter, randomized, double blind, placebo controlled trial, Neurol. 43: in press (1993).Google Scholar
- 4.H.S. Panitch, Interferons in multiple sclerosis. A review of the evidence, Drugs. 44(6): 946–962 (1992).Google Scholar
- 6.S. Dhib-Jalbut, D.E. McFarlin, Immunology of multiple sclerosis, Ann Allergy. 64: 433–444 (1989).Google Scholar
- 7.H.S. Panitch, J.S. Folus, K.P. Johnson, Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis, Abstract, Ann Neurol. 22: 139 (1987a).Google Scholar
- 9.H.S. Panitch, J.S. Folus, K.P. Johnson, Activated suppressor cells inhibit synthesis of interferon-―in patients with multiple sclerosis patients and normal subjects, Abstract, J Neuroimmunol. In press (1992b).Google Scholar
- 11.M.B. Bornstein, A. Miller, S. Slagle et al, A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosisA pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis, N Engl J Med. 317: 408–414 (1987).Google Scholar
- 12.M.B. Bornstein, K.P. Johnson, Treatment of multiple sclerosis with Copolymer I, in: “Handbook of Multiple Sclerosis,” S.D. Cook, ed., Marcel Dekker, Inc., New York and Basel (1990).Google Scholar